198 related articles for article (PubMed ID: 24414744)
1. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.
Cobo-Ibáñez T; Descalzo MÁ; Loza-Santamaría E; Carmona L; Muñoz-Fernández S
Rheumatol Int; 2014 Jul; 34(7):953-61. PubMed ID: 24414744
[TBL] [Abstract][Full Text] [Related]
2. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
Curtis JR; Yang S; Patkar NM; Chen L; Singh JA; Cannon GW; Mikuls TR; Delzell E; Saag KG; Safford MM; DuVall S; Alexander K; Napalkov P; Winthrop KL; Burton MJ; Kamauu A; Baddley JW
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):990-7. PubMed ID: 24470378
[TBL] [Abstract][Full Text] [Related]
3. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.
Greenberg JD; Reed G; Kremer JM; Tindall E; Kavanaugh A; Zheng C; Bishai W; Hochberg MC;
Ann Rheum Dis; 2010 Feb; 69(2):380-6. PubMed ID: 19359261
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis.
Thomas K; Lazarini A; Kaltsonoudis E; Voulgari PV; Drosos AA; Repa A; Sali AMI; Sidiropoulos P; Tsatsani P; Gazi S; Evangelia A; Boki KA; Katsimbri P; Boumpas D; Fragkiadaki K; Tektonidou MG; Sfikakis PP; Karagianni K; Sakkas LI; Grika EP; Vlachoyiannopoulos PG; Evangelatos G; Iliopoulos A; Dimitroulas T; Garyfallos A; Melissaropoulos K; Georgiou P; Areti M; Georganas C; Vounotrypidis P; Georgiopoulos G; Kitas GD; Vassilopoulos D
Rheumatology (Oxford); 2021 May; 60(5):2223-2230. PubMed ID: 33295627
[TBL] [Abstract][Full Text] [Related]
5. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
6. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
[TBL] [Abstract][Full Text] [Related]
7. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
9. Cancer in patients with rheumatic diseases exposed to TNF antagonists.
Carmona L; Abasolo L; Descalzo MA; Pérez-Zafrilla B; Sellas A; de Abajo F; Gomez-Reino JJ; ;
Semin Arthritis Rheum; 2011 Aug; 41(1):71-80. PubMed ID: 21093020
[TBL] [Abstract][Full Text] [Related]
10. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
Simon TA; Askling J; Lacaille D; Franklin J; Wolfe F; Covucci A; Suissa S; Hochberg MC;
Arthritis Res Ther; 2010; 12(2):R67. PubMed ID: 20398273
[TBL] [Abstract][Full Text] [Related]
11. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.
Curtis JR; Xie F; Chen L; Baddley JW; Beukelman T; Saag KG; Spettell C; McMahan RM; Fernandes J; Winthrop K; Delzell E
Ann Rheum Dis; 2011 Aug; 70(8):1401-6. PubMed ID: 21586439
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial.
Mariette X; Rouanet S; Sibilia J; Combe B; Le Loët X; Tebib J; Jourdan R; Dougados M
Ann Rheum Dis; 2014 Aug; 73(8):1508-14. PubMed ID: 23723317
[TBL] [Abstract][Full Text] [Related]
14. Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR.
Ranza R; de la Vega MC; Laurindo IMM; Gómez MG; Titton DC; Kakehasi AM; Brigante A; Benitez A; Ranzolin A; Granel A; Cappuccio AM; Quinteros A; Hayata ALS; Smichowski A; Duarte ÂLBP; Kahlow BS; Andia CS; Brenol CV; Velozo E; Mussano E; Soriano ER; Christopoulos GB; da Rocha Castelar Pinheiro G; de Castro GRW; Casado G; da Silveira Carvalho HM; Exeni IE; da Silveira IG; Petkovic I; Pereira IA; da Costa IP; Rosa JE; Miranda JRS; de Moraes JCB; Bertolo MB; Buhl M; Lázaro MA; da Sauma MFLC; de Medeiros Pinheiro M; Díaz M; de Vechi MVSS; Cerda OL; Astesana P; Curi PF; Louzada-Jr P; Teodoro RB; Toledo RA; Papasidero S; Valim V; Fernandes V; Saurit V; Bianchi WA; ; de Melo Costa Pinto R; Descalzo MA; Gomez-Reino JJ
Clin Rheumatol; 2019 Aug; 38(8):2129-2139. PubMed ID: 31016578
[TBL] [Abstract][Full Text] [Related]
15. The risk of infections with biologic therapies for rheumatoid arthritis.
Furst DE
Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
[TBL] [Abstract][Full Text] [Related]
16. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry.
Thomas L; Canoui-Poitrine F; Gottenberg JE; Economu-Dubosc A; Medkour F; Chevalier X; Bastuji-Garin S; Le Louët H; Farrenq V; Claudepierre P
J Rheumatol; 2012 May; 39(5):893-8. PubMed ID: 22505694
[TBL] [Abstract][Full Text] [Related]
17. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI; Patarata E; Subesinghe S; Hyrich KL; Galloway JB
Rheumatology (Oxford); 2018 Jun; 57(6):997-1001. PubMed ID: 29529307
[TBL] [Abstract][Full Text] [Related]
18. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice.
Toussirot E; Pertuiset E; Sordet C; Augé B; Wendling D; Pallot-Pradès B; Collet P; Lohse A; Balblanc JC
Joint Bone Spine; 2010 Mar; 77(2):142-5. PubMed ID: 20171921
[TBL] [Abstract][Full Text] [Related]
19. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
Mariette X; Gottenberg JE; Ravaud P; Combe B
Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
[TBL] [Abstract][Full Text] [Related]
20. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
